
|Articles|July 14, 2022
AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and Veterans
Advertisement
AiCure announced the DHA PTSD-DT Program will deploy AiCure's AI platform in its post-traumatic stress disorder (PTSD) adaptive platform trial (APT) to simultaneously evaluate the efficacy of multiple PTSD treatments in both active service members and veterans.
AiCure will work with the DHA PTSD-DT Program to deploy its medication adherence platform to guide patients in their compliance to complex treatment regimens, as well as its digital biomarker solution to unobtrusively capture the subtleties of a patient's response.
Read more about the program
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Recruitment in the Age of AI: Q&A with John Worden, Javara
2
What It Actually Means to Embed the Patient Voice in Trial Design
3
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
4
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
5




